FDA Approves New Pfizer Regimen for Advanced Breast Cancer

The U.S. FDA has granted approval for Pfizer's Ibrance, in combination with other therapies, to treat adult patients with a specific type of advanced or metastatic breast cancer. This new regimen is intended for maintenance treatment following initial therapy. The decision is based on trial results showing a reduced risk of disease progression.